Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system.

Standard

Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. / Cordiglieri, Chiara; Francesca, Odoardi; Zhang, Bo; Nebel, Merle; Kawakami, Naoto; Klinkert, Wolfgang E F; Lodygin, Dimtri; Lühder, Fred; Breunig, Esther; Schild, Detlev; Ulaganathan, Vijay Kumar; Dornmair, Klaus; Dammermann, Werner; Potter, Barry V L; Guse, Andreas H.; Flügel, Alexander.

in: BRAIN, Jahrgang 133, Nr. 7, 7, 2010, S. 1930-1943.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Cordiglieri, C, Francesca, O, Zhang, B, Nebel, M, Kawakami, N, Klinkert, WEF, Lodygin, D, Lühder, F, Breunig, E, Schild, D, Ulaganathan, VK, Dornmair, K, Dammermann, W, Potter, BVL, Guse, AH & Flügel, A 2010, 'Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system.', BRAIN, Jg. 133, Nr. 7, 7, S. 1930-1943. <http://www.ncbi.nlm.nih.gov/pubmed/20519328?dopt=Citation>

APA

Cordiglieri, C., Francesca, O., Zhang, B., Nebel, M., Kawakami, N., Klinkert, W. E. F., Lodygin, D., Lühder, F., Breunig, E., Schild, D., Ulaganathan, V. K., Dornmair, K., Dammermann, W., Potter, B. V. L., Guse, A. H., & Flügel, A. (2010). Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. BRAIN, 133(7), 1930-1943. [7]. http://www.ncbi.nlm.nih.gov/pubmed/20519328?dopt=Citation

Vancouver

Cordiglieri C, Francesca O, Zhang B, Nebel M, Kawakami N, Klinkert WEF et al. Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. BRAIN. 2010;133(7):1930-1943. 7.

Bibtex

@article{7a8dd97a93f54dac8d7a0417c5ac5dbd,
title = "Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system.",
abstract = "Nicotinic acid adenine dinucleotide phosphate represents a newly identified second messenger in T cells involved in antigen receptor-mediated calcium signalling. Its function in vivo is, however, unknown due to the lack of biocompatible inhibitors. Using a recently developed inhibitor, we explored the role of nicotinic acid adenine dinucleotide phosphate in autoreactive effector T cells during experimental autoimmune encephalomyelitis, the animal model for multiple sclerosis. We provide in vitro and in vivo evidence that calcium signalling controlled by nicotinic acid adenine dinucleotide phosphate is relevant for the pathogenic potential of autoimmune effector T cells. Live two photon imaging and molecular analyses revealed that nicotinic acid adenine dinucleotide phosphate signalling regulates T cell motility and re-activation upon arrival in the nervous tissues. Treatment with the nicotinic acid adenine dinucleotide phosphate inhibitor significantly reduced both the number of stable arrests of effector T cells and their invasive capacity. The levels of pro-inflammatory cytokines interferon-gamma and interleukin-17 were strongly diminished. Consecutively, the clinical symptoms of experimental autoimmune encephalomyelitis were ameliorated. In vitro, antigen-triggered T cell proliferation and cytokine production were evenly suppressed. These inhibitory effects were reversible: after wash-out of the nicotinic acid adenine dinucleotide phosphate antagonist, the effector T cells fully regained their functions. The nicotinic acid derivative BZ194 induced this transient state of non-responsiveness specifically in post-activated effector T cells. Na{\"i}ve and long-lived memory T cells, which express lower levels of the putative nicotinic acid adenine dinucleotide phosphate receptor, type 1 ryanodine receptor, were not targeted. T cell priming and recall responses in vivo were not reduced. These data indicate that the nicotinic acid adenine dinucleotide phosphate/calcium signalling pathway is essential for the recruitment and the activation of autoaggressive effector T cells within their target organ. Interference with this signalling pathway suppresses the formation of autoimmune inflammatory lesions and thus might qualify as a novel strategy for the treatment of T cell mediated autoimmune diseases.",
author = "Chiara Cordiglieri and Odoardi Francesca and Bo Zhang and Merle Nebel and Naoto Kawakami and Klinkert, {Wolfgang E F} and Dimtri Lodygin and Fred L{\"u}hder and Esther Breunig and Detlev Schild and Ulaganathan, {Vijay Kumar} and Klaus Dornmair and Werner Dammermann and Potter, {Barry V L} and Guse, {Andreas H.} and Alexander Fl{\"u}gel",
year = "2010",
language = "Deutsch",
volume = "133",
pages = "1930--1943",
journal = "BRAIN",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system.

AU - Cordiglieri, Chiara

AU - Francesca, Odoardi

AU - Zhang, Bo

AU - Nebel, Merle

AU - Kawakami, Naoto

AU - Klinkert, Wolfgang E F

AU - Lodygin, Dimtri

AU - Lühder, Fred

AU - Breunig, Esther

AU - Schild, Detlev

AU - Ulaganathan, Vijay Kumar

AU - Dornmair, Klaus

AU - Dammermann, Werner

AU - Potter, Barry V L

AU - Guse, Andreas H.

AU - Flügel, Alexander

PY - 2010

Y1 - 2010

N2 - Nicotinic acid adenine dinucleotide phosphate represents a newly identified second messenger in T cells involved in antigen receptor-mediated calcium signalling. Its function in vivo is, however, unknown due to the lack of biocompatible inhibitors. Using a recently developed inhibitor, we explored the role of nicotinic acid adenine dinucleotide phosphate in autoreactive effector T cells during experimental autoimmune encephalomyelitis, the animal model for multiple sclerosis. We provide in vitro and in vivo evidence that calcium signalling controlled by nicotinic acid adenine dinucleotide phosphate is relevant for the pathogenic potential of autoimmune effector T cells. Live two photon imaging and molecular analyses revealed that nicotinic acid adenine dinucleotide phosphate signalling regulates T cell motility and re-activation upon arrival in the nervous tissues. Treatment with the nicotinic acid adenine dinucleotide phosphate inhibitor significantly reduced both the number of stable arrests of effector T cells and their invasive capacity. The levels of pro-inflammatory cytokines interferon-gamma and interleukin-17 were strongly diminished. Consecutively, the clinical symptoms of experimental autoimmune encephalomyelitis were ameliorated. In vitro, antigen-triggered T cell proliferation and cytokine production were evenly suppressed. These inhibitory effects were reversible: after wash-out of the nicotinic acid adenine dinucleotide phosphate antagonist, the effector T cells fully regained their functions. The nicotinic acid derivative BZ194 induced this transient state of non-responsiveness specifically in post-activated effector T cells. Naïve and long-lived memory T cells, which express lower levels of the putative nicotinic acid adenine dinucleotide phosphate receptor, type 1 ryanodine receptor, were not targeted. T cell priming and recall responses in vivo were not reduced. These data indicate that the nicotinic acid adenine dinucleotide phosphate/calcium signalling pathway is essential for the recruitment and the activation of autoaggressive effector T cells within their target organ. Interference with this signalling pathway suppresses the formation of autoimmune inflammatory lesions and thus might qualify as a novel strategy for the treatment of T cell mediated autoimmune diseases.

AB - Nicotinic acid adenine dinucleotide phosphate represents a newly identified second messenger in T cells involved in antigen receptor-mediated calcium signalling. Its function in vivo is, however, unknown due to the lack of biocompatible inhibitors. Using a recently developed inhibitor, we explored the role of nicotinic acid adenine dinucleotide phosphate in autoreactive effector T cells during experimental autoimmune encephalomyelitis, the animal model for multiple sclerosis. We provide in vitro and in vivo evidence that calcium signalling controlled by nicotinic acid adenine dinucleotide phosphate is relevant for the pathogenic potential of autoimmune effector T cells. Live two photon imaging and molecular analyses revealed that nicotinic acid adenine dinucleotide phosphate signalling regulates T cell motility and re-activation upon arrival in the nervous tissues. Treatment with the nicotinic acid adenine dinucleotide phosphate inhibitor significantly reduced both the number of stable arrests of effector T cells and their invasive capacity. The levels of pro-inflammatory cytokines interferon-gamma and interleukin-17 were strongly diminished. Consecutively, the clinical symptoms of experimental autoimmune encephalomyelitis were ameliorated. In vitro, antigen-triggered T cell proliferation and cytokine production were evenly suppressed. These inhibitory effects were reversible: after wash-out of the nicotinic acid adenine dinucleotide phosphate antagonist, the effector T cells fully regained their functions. The nicotinic acid derivative BZ194 induced this transient state of non-responsiveness specifically in post-activated effector T cells. Naïve and long-lived memory T cells, which express lower levels of the putative nicotinic acid adenine dinucleotide phosphate receptor, type 1 ryanodine receptor, were not targeted. T cell priming and recall responses in vivo were not reduced. These data indicate that the nicotinic acid adenine dinucleotide phosphate/calcium signalling pathway is essential for the recruitment and the activation of autoaggressive effector T cells within their target organ. Interference with this signalling pathway suppresses the formation of autoimmune inflammatory lesions and thus might qualify as a novel strategy for the treatment of T cell mediated autoimmune diseases.

M3 - SCORING: Zeitschriftenaufsatz

VL - 133

SP - 1930

EP - 1943

JO - BRAIN

JF - BRAIN

SN - 0006-8950

IS - 7

M1 - 7

ER -